Is Abbott Laboratories a good investment? Abbott Laboratories (ABT.SW) is currently trading at 84.50 CHF.
In terms of valuation, the stock trades at a P/E ratio of 30.29. This high multiple suggests investors have priced in significant future growth expectations.
Earnings Schedule: Abbott Laboratories is expected to release its next earnings report on July 16, 2026.
For income investors, Abbott Laboratories pays a dividend yield of 3.03%. With a payout ratio of 67%, the dividend appears sustainable.
Yes, it pays an annual dividend of 1.97 CHF (3.03% yield).
Abbott Laboratories is classified as a Stock. You can compare it against 12 other assets in the "Related Symbols" list on this page.
The next earnings date is projected to be July 16, 2026. The company currently has a trailing EPS of 2.79.
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.
3.03% (5y avg: 1.87%)
1.97 CHF
April 15, 2026
67.23%
| Year | Total Dividends |
|---|---|
| 2027 | 0.55 CHF |
| Feb. 15, 2027 (estimated) | 0.5459 |
| 2026 | 2.04 CHF |
| Nov. 16, 2026 (estimated) | 0.5181 |
| Aug. 17, 2026 (estimated) | 0.5226 |
| May 15, 2026 | 0.4952 |
| Feb. 13, 2026 | 0.5062 |
| 2025 | 1.97 CHF |
| Nov. 17, 2025 | 0.4702 |
| Aug. 15, 2025 | 0.4737 |
| May 15, 2025 | 0.4866 |
| Feb. 14, 2025 | 0.5387 |
| 2024 | 1.94 CHF |
| Nov. 15, 2024 | 0.4749 |
| Aug. 15, 2024 | 0.4927 |
| May 15, 2024 | 0.5031 |
| Feb. 15, 2024 | 0.4687 |
| 2023 | 1.83 CHF |
| Nov. 15, 2023 | 0.4635 |
| Aug. 15, 2023 | 0.4383 |
| May 15, 2023 | 0.4540 |
| Feb. 15, 2023 | 0.4732 |
| 2022 | 1.80 CHF |
| Nov. 15, 2022 | 0.4707 |
| Aug. 15, 2022 | 0.4626 |
| May 16, 2022 | 0.4395 |
| Feb. 15, 2022 | 0.4283 |
| 2021 | 1.64 CHF |
| Nov. 15, 2021 | 0.4159 |
| Aug. 16, 2021 | 0.4122 |
| May 17, 2021 | 0.4154 |
| Feb. 16, 2021 | 0.4000 |
| 2020 | 1.36 CHF |
| Nov. 16, 2020 | 0.3284 |
| Aug. 15, 2020 | 0.3380 |
| May 15, 2020 | 0.3459 |
| Feb. 14, 2020 | 0.3486 |
| 2019 | 1.27 CHF |
| Nov. 15, 2019 | 0.3195 |
| Aug. 15, 2019 | 0.3153 |
| May 15, 2019 | 0.3204 |
| Feb. 15, 2019 | 0.3139 |
| 2018 | 1.10 CHF |
| Nov. 15, 2018 | 0.2778 |
| Aug. 15, 2018 | 0.2800 |
| May 15, 2018 | 0.2695 |
| Feb. 15, 2018 | 0.2730 |
| 2017 | 1.05 CHF |
| Nov. 15, 2017 | 0.2587 |
| Aug. 15, 2017 | 0.2555 |
| May 15, 2017 | 0.2666 |
| Feb. 15, 2017 | 0.2713 |
Yearly aggregated dividends
|
Abbott Laboratories
May 15, 2026 Paid
Dividend
0.49521 CHF |
|
Abbott Laboratories
Feb 13, 2026 Paid
Dividend
0.50623 CHF |
|
Abbott Laboratories
Nov 17, 2025 Paid
Dividend
0.47023 CHF |
|
Abbott Laboratories
Aug 15, 2025 Paid
Dividend
0.47371 CHF |
| Split Date | Split Ratio to 1 |
|---|---|
| Jan. 3, 2013 | 2.000000 |
Unlock detailed news and exclusive insights with our Premium subscription.
See Pricing Plans
Community Discussion